Target intelligence / Profile preview

Dynein axonemal intermediate chain 2 (DNAI2)

Target
DNAI2
Molecular classification
Other (Motor protein, structural component of axonemal dynein complex, not a receptor, enzyme, transporter, or typical drug target)
01

Overview

Dynein axonemal intermediate chain 2 (DNAI2) is a structural protein encoded by the DNAI2 gene, forming a key intermediate chain within the axonemal dynein complex that powers the movement of motile cilia and flagella[1][3]. DNAI2 is essential for the assembly and function of outer dynein arms in respiratory cilia and sperm flagella, underlying its crucial roles in respiratory tract mucociliary clearance and fertility[1][3][5]. Mutations in DNAI2 cause an autosomal recessive disorder known as primary ciliary dyskinesia (CILD9), which manifests as lung disease, male infertility, and, more rarely, female subfertility due to defects in ciliary and flagellar motility[3][5][9]. Studies in mouse and other models support its involvement in both ciliary assembly and gametogenesis. DNAI2 may interact with signaling pathways such as STAT3, influencing tissue-specific proliferation and apoptosis, but it is not considered a classic pharmacological or therapeutic drug target[5].

Other names
CILD9DIC2oda6axonemal dynein intermediate chain 2dynein intermediate chain 2dynein, axonemal, intermediate polypeptide 2
02

Biological functions

Ciliary and flagellar motilityassembly of the axonemal dynein complexregulation of gametogenesispotential interaction with STAT3 (implicated in cell proliferation and apoptosis in specific tissues)
03

Disease associations

Ciliopathy (especially primary ciliary dyskinesia, PCD)infertility (male and female)lung dysfunction
04

Safety considerations

no direct targeting; mutations cause genetic disease, not a drug safety issue
05

Biomarkers

may serve as a genetic marker for primary ciliary dyskinesia but not an established pharmacological biomarker

Beyond the preview

Go deeper on Dynein axonemal intermediate chain 2 (DNAI2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal intermediate chain 2 (DNAI2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call